Antimicrobials have been widely used to fight diseases,
including sexually transmitted infections (STIs), for nearly
80 years. Penicillin, the world’s first antibiotic, was
used for the first time to treat and cure syphilis in 1943.
However, bacteria that cause STIs have fought back so that
many of the antibiotics once used to treat them no longer
work, even as STIs continue to cause high rates of
infections worldwide.
In 2016, the World Health
Organization (WHO) estimated the annual global burden of
curable STIs to be 376 million new infections mainly of
gonorrhoea, chlamydia, syphilis and trichomoniasis – over 1
million cases everyday. However, the emergence of
antimicrobial-resistant strains of bacteria (that cause
STIs) is making STIs difficult to treat and may even render
the disease incurable as these antimicrobial-resistant
strains become dominant.
Heading the list of bacterial
STIs that have stopped responding to many drugs used earlier
to treat them is gonorrhoea. The WHO estimates that 82.4
million people were newly infected with gonorrhoea in 2020.
As per a study the gonorrhoea causing bacteria Neisseria
gonorrhoea has already become resistant to penicillin,
tetracycline, and fluoroquinolones. And now there is a
rising global emergence of azithromycin/ ceftriaxone
resistant Neisseria gonorrhoeae that threatens the current
WHO recommended azithromycin/ceftriaxone dual therapy to
treat gonorrhoea, which is being used in many
countries.
Dr Rossaphorn Kittiyaowamarn, Chief of
Bangrak STIs Center, Department of Disease Control, Ministry
of Public Health, Thailand, told CNS that the first case of
antibiotic non-susceptible Neisseria gonorrhoea (which is
the most common bacterial sexually transmitted infections in
Thailand, affecting both men and women) was reported in
Thailand in 2017 and the number of cases is rising.
Therefore, it is necessary to expand antimicrobial-resistant
gonorrhoea surveillance and strengthen gonorrhoea laboratory
tests to guide proper antibiotics use for reducing the risk
of antimicrobial resistance in the coming
future.
Professor Tadashi Kimura, Chairperson of
Executive Board of Japan Society of Obstetrics and
Gynaecology and Professor of Gynaecology and Obstetrics,
Osaka University School of Medicine, also raised similar
concerns. He said that while MRSA (Methicillin-Resistant
Staphylococcus Aureus – MRSA) is the most prevalent
antimicrobial-resistant bacterial strain in Japan,
Ceftriaxone-resistant gonorrhoea cases are there and one has
to be very careful and prevent this drug resistant strain
from spreading. Another problem he was concerned about is
that STIs are often treated in ‘underground’ clinics in
Japan (for a variety of reasons), which do not have the
wherewithal to do drug susceptibility tests and so cannot
detect antimicrobial resistance, thus, not helping in
checking the spread of antimicrobial resistance.
Due
to limited access and affordability of STI laboratory
diagnosis at the primary level of care where the majority of
STI cases seek care, syndromic case management remains the
cornerstone of STI control in many developing countries. Dr
Ishwar Gilada, President of AIDS Society of India, and
Governing Council member of International AIDS Society
voiced his concern about this in lead up to the
International Conference on Family Planning 2022 (ICFP
2022).
Dr Gilada said that in the case of STIs, other
than HIV infection, patients are often treated empirically
based upon their clinical presentation, without obtaining a
microbiologic diagnosis.
“This syndromic management
of STIs is a culprit resulting in developing antimicrobial
resistance. Earlier molecular tests (such as,
Cartridge-based nucleic acid amplification test or CBNAAT or
polymerase chain reaction (PCR) tests) were not available
and at times it was cheaper to treat than diagnose STIs. But
now we are in 2022, and science is much more
advanced.”
Etiological diagnosis of STIs using
laboratory tests to identify the causative agent is
important. Syndromic diagnosis may miss individuals with
asymptomatic STIs and thus help in spreading antimicrobial
resistance, he said.
Regarding treatment of HIV, he
said that some doctors have been treating HIV patients with
the same old drugs to which their patients have stopped
responding. “One example of human made antimicrobial
resistance is the use of single dose nevirapine in the past
for prevention of mother to child transmission of HIV. Its
use as a single drug has caused a great harm by creating
antimicrobial resistance to that class of antiviral
drug.”
According to Dr Gilada it is important to do
a drug sensitivity test (DST) before starting a patient on
antiretroviral therapy. But in many developing countries,
including India, “we are using a deductive logic” and
not doing a DST before putting the person on an
antiretroviral regimen that is best suited for him/ her/
them. He also calls for a careful use of new antiretroviral
medicines, like Dolutegravir, which has been used as a
preferred combination antiretroviral medicine since 2018 by
most countries. Apart from being highly effective and well
tolerated, it has a high genetic barrier to developing
resistance. But cases of resistance to this new antiviral
have already surfaced. One has to use antimicrobials
(including the new ones) very judiciously so that they do
not lose their effectiveness.
“we should train
medical caregivers properly both by way of formal training
and by way of up-to-date knowledge” so that they can make
a proper diagnosis and ensure rational use of existing
drugs. If that is not done, we are going to face a problem
of both primary as well as secondary resistance to
antimicrobial drugs, Dr Gilada cautions.
Chlamydia and
syphilis are other STIs to watch out. Macrolide resistance
in syphilis is now present in many geographic regions.
Although significant antibiotic resistance has not emerged
in Chlamydia species pathogenic to humans, these organisms
can express significant resistant phenotypes. So clinicians
have to remain vigilant for the emergence of resistant
strains in the future.
Thomas Joseph, Head,
Antimicrobial Stewardship and Awareness Unit, at WHO,
rightly points out “if antibiotics and other
antimicrobials lose their effectiveness, we lose the ability
not only to treat infections, but also to manage these other
health conditions. A person with a drug-resistant infection
is more likely to be sick and absent from work and family
commitments, for longer, and require more expensive
medicines and medical care. This has major implications on
health-care costs and productivity, both for patients and
their caregivers, as well as more broadly on the health
system and national economy.”
Antimicrobial
resistance is already among the top threats looming over
global health security today. Will we be able to protect the
medicines that protect us? Let us hope the answer in the
womb of time is affirmative. But as of now, a lot depends on
actions we all take unitedly across sectors and geographies,
to stem the tide of antimicrobial resistance.
Shobha
Shukla – CNS (Citizen News Service)
(Shobha Shukla
is the award-winning founding Managing Editor and Executive
Director of CNS (Citizen News Service) and is a feminist,
health and development justice advocate. She is a former
senior Physics faculty of prestigious Loreto Convent College
and current Coordinator of Asia Pacific Regional Media
Alliance for Health and Development (APCAT Media). Follow
her on Twitter @shobha1shukla or read her writings here www.bit.ly/ShobhaShukla)
–
Shared under Creative Commons
(CC)
© Scoop Media



















Discussion about this post